Qiagen (NYSE:QGEN) Sees Large Volume Increase

Shares of Qiagen (NYSE:QGEN) saw an uptick in trading volume on Monday . 1,375,287 shares traded hands during mid-day trading, an increase of 12% from the previous session’s volume of 1,230,574 shares.The stock last traded at $43.07 and had previously closed at $42.98.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on QGEN. Citigroup dropped their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, February 8th. Stifel Nicolaus lowered their price objective on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research report on Wednesday, May 1st. JPMorgan Chase & Co. upped their price objective on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, February 8th. Finally, Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.95.

Qiagen Price Performance

The firm’s fifty day moving average is $42.50 and its two-hundred day moving average is $42.83. The company has a market cap of $9.80 billion, a P/E ratio of 28.79, a P/E/G ratio of 3.64 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The business had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The business’s revenue was down 5.4% on a year-over-year basis. As a group, analysts anticipate that Qiagen will post 2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Lindbrook Capital LLC lifted its holdings in shares of Qiagen by 21.6% in the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock valued at $58,000 after acquiring an additional 237 shares during the last quarter. Xponance Inc. lifted its holdings in shares of Qiagen by 2.7% in the 4th quarter. Xponance Inc. now owns 9,609 shares of the company’s stock valued at $417,000 after acquiring an additional 253 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Qiagen by 66.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after purchasing an additional 283 shares during the period. CWM LLC raised its position in Qiagen by 19.1% in the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after purchasing an additional 358 shares during the period. Finally, Signaturefd LLC raised its position in Qiagen by 9.0% in the 3rd quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock worth $190,000 after purchasing an additional 385 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.